PortViewPortView
Acasti Pharma logo

Acasti Pharma (ACST) Stock Analysis

NASDAQHealthcareBiotechnology

$3.37+4.01%
1-year price historyRange $2.05 – $3.60
52-week range$3.37
$1.98$3.60

What Acasti Pharma does

Acasti Pharma Inc. operates as a biopharmaceutical firm, concentrating its efforts on developing and marketing pharmaceutical solutions specifically for cardiovascular conditions. The company is currently exploring potential strategic alliances to further the clinical development of its drug candidate, CaPre. This Canadian company, which was established in 2002, has its main offices located in Laval.

Key metrics

Market cap
$34.17M
P/E (TTM)
-2.36
EPS (TTM)
$-1.43
Beta
1.52
Dividend yield
0.00%
Revenue / share
$0.00
50-day avg
$3.05
200-day avg
$2.99
52-week high
$3.60
52-week low
$1.98
CEO
Prashant Kohli

ETFs linked to ACST

Broad-market and Healthcare sector ETFs an investor holding Acasti Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ACST fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze ACST in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Acasti Pharma?
Acasti Pharma trades under the ticker ACST on NASDAQ.
Which exchange is ACST listed on?
ACST is listed on NASDAQ.
What sector does Acasti Pharma operate in?
Acasti Pharma is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze ACST in a portfolio?
PortView shows ACST's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.